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Abstract
Background: Hypoxia influences tumor growth by inducing angiogenesis and genetic alterations.
Hypoxia-inducible factor 1α (HIF-1α), p53, and vascular endothelial growth factor (VEGF) are all
important factors in the mechanisms inherent to tumor progression. In this work, we have
investigated the clinicopathologic significance of HIF-1α, p53, and VEGF expression and
preoperative serum VEGF (sVEGF) level in gastric cancer.
We immunohistochemically assessed the HIF-1α, p53, and VEGF expression patterns in 114
specimens of gastric cancer. Additionally, we determined the levels of preoperative serum VEGF
(sVEGF).
Results: The positive rates of p53 and HIF-1α (diffuse, deep, intravascular pattern) were 38.6%
and 15.8%, respectively. The VEGF overexpression rate was 57.9%. p53 and HIF-1α were
correlated positively with the depth of invasion (P = 0.015, P = 0.001, respectively). Preoperative
sVEGF and p53 levels were correlated significantly with lymph node involvement (P = 0.010, P =
0.040, respectively). VEGF overexpression was more frequently observed in the old age group (≥
60 years old) and the intestinal type (P = 0.013, P = 0.014, respectively). However, correlations
between preoperative sVEGF level and tissue HIF-1α, VEGF, and p53 were not observed. The
median follow-up duration after operation was 24.5 months. HIF-1α was observed to be a poor
prognostic factor of disease recurrence or progression (P = 0.002).
Conclusion: p53, HIF-1α and preoperative sVEGF might be markers of depth of invasion or lymph
node involvement. HIF-1α expression was a poor prognostic factor of disease recurrence or
progression in patients with gastric cancers.
Published: 1 May 2008
BMC Cancer 2008, 8:123 doi:10.1186/1471-2407-8-123
Received: 11 January 2008
Accepted: 1 May 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/123
© 2008 Oh et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:123 http://www.biomedcentral.com/1471-2407/8/123
Page 2 of 7
(page number not for citation purposes)
Background
In gastric cancer, lymph node (LN) metastasis and distant
metastasis have been established as the standard prognos-
tic factors for relapse-free or overall survival. Angiogenesis
is a crucial mediator of tumor progression. As tumors
expand, diffusion distances from the existing vascular sup-
ply increase, resulting in hypoxia [1]. Hypoxia limits
tumor growth, and tumors with poor vascularization fail
to grow and form metastases [2]. However, hypoxia also
affects tumor growth positively, by inducing cellular adap-
tations as well as angiogenesis and genetic alterations [3].
Hypoxia-inducible factor-1α (HIF-1α) is a transcription
factor for many genes recognized to control the delivery of
oxygen and nutrients via the induction of angiogenesis
and glycolysis [4]. HIF-1α activates the transcription of
vascular endothelial growth factor (VEGF), a key factor in
tumor angiogenesis, and the expression of glucose trans-
porters, glycolytic enzymes, and growth factors, which
may promote tumor cell survival under hypoxic condi-
tions [5].
Hypoxia has also been reported to induce wild-type p53
via a different pathway than DNA-damaging agents [6].
The hypoxic/anoxic induction of p53 selects for tumor
cells that lack functional p53, and hence evidence dimin-
ished apoptotic potential [7]. The interaction of HIF-1α
and p53, which affects tumor growth and clinical out-
come, remains obscure to some extent. The overexpres-
sion of the HIF-1α and p53 proteins has been
demonstrated in a variety of human cancers via immuno-
histochemistry (IHC) [8].
However, in gastric cancer, correlations of p53, HIF-1α
and VEGF expression with preoperative serum VEGF
(sVEGF) level with regard to clinicopathologic signifi-
cance and prognosis are currently a matter of debate. In
this study, we have examined, via IHC, the expression of
HIF-1α, VEGF, and p53 proteins in surgical gastric cancer
specimens. Also, we have examined preoperative sVEGF
level for assessing the cliniclpathological significance and
co-relation of each factor.
Methods
Patients and specimens
Paraffin-embedded tumor specimens from 114 patients,
representing patients who had undergone curative gast-
rectomies at the Dong-A University Hospital and consec-
utively affiliated hospitals from March 2003, were utilized
to evaluate the clinical significance of protein expression.
None of the patients had received any preoperative treat-
ments. The study was approved by the ethics committee
(Dong-A Medical Center Institutional Review Board) and
informed written consent was obtained from all patients
before study entry.
Blood samples and assays of sVEGF level
Peripheral venous blood samples were obtained within 7
days prior to gastrectomy, collected in plain tubes, permit-
ted to clot, and were centrifuged at 3,000 rpm for 10 min
at 4°C within one hour of collection in order to obtain the
serum. The serum was aliquoted and stored at -270°C
until being assayed. The VEGF levels from the sera of
patients and the standard solutions supplied were meas-
ured with a commercially available system (Quantikine
hVEGF Immunoassay, R&D Systems, USA) in accordance
with the manufacturer's instructions. All serum samples
were measured by an investigator who was blinded to the
clinical data.
Immunohistochemistry
Paraffin-embedded tissues were cut into 5-μm-thick sec-
tions and subjected to immunohistochemical analyses
conducted via the avidin-biotin-peroxidase complex
method.
HIF-1α, p53, and VEGF
The primary antibody for HIF-1α protein used in this
study was monoclonal IgG 2b (clone H1α 67) (1:50;
Novus Biologicals, Littleton, CO, USA). The primary anti-
bodies used for VEGF proteins were rabbit polyclonal Ab
A-20 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and p53 protein mouse monoclonal antibody
(1:100; Dako, Glostrup, Denmark). After incubation with
primary antibody, the sections were incubated with the
secondary antibody and avidin-biotin-peroxidase com-
plex. The slides were counterstained with H&E.
Interpretation
HIF-1α
A positive value was recorded when nuclear staining was
observed in >1% of cancer cells. Cytoplasmic staining was
not counted. Sites of positive expression were also
described in the following terms: superficial, deep-sited,
diffuse, and vascular invasion.
P53
A positive value was recorded if distinct and strong
nuclear staining was observed in >10% of the cancer cells.
VEFG
We evaluated the proportion (+1~+3) and intensity
(+1~+3) of cytoplasmic staining of the tumor cells. We
then multiplied the proportion value by the intensity
value. After calculating the VEGF average value, underex-
pression of VEGF was defined below the average value;
VEGF overexpression was defined as above average values.
All evaluations for immunostaining were conducted by
two independent observers with no knowledge of the
patient's clinical status. A double-headed light microscope
was utilized.BMC Cancer 2008, 8:123 http://www.biomedcentral.com/1471-2407/8/123
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Each patient underwent gastrectomy, and D2 or more
extended lymph node dissection was usually conducted.
Tissue specimens were examined for the following charac-
teristics: depth of tumor invasion, presence of lymph
mode involvement, macroscopic and histological type,
tumor size and lymphovascular invasion. The staging of
gastric cancer and the clinicopathological factors utilized
in this study were based on the sixth edition of the Amer-
ican Joint Committee on Cancer (AJCC) Cancer Staging
Manual [9].
Statistical analysis
The two-tailed χ2 test was conducted to determine the sig-
nificance of the difference between the covariates. sVEGF
data are presented as median value (interquartile range),
with nonparametric analyses being employed to assess
differences. The Mann-Whitney U test were used to evalu-
ate differences between groups. sVEGF cut-off value for
survival analysis determined by ROC curve. Survival dura-
tions were calculated via the Kaplan-Meier method. The
log-rank test was employed to compare cumulative sur-
vival in the patient groups. In all tests, P < 0.05 was the
threshold of statistical significance. The SPSS software
program (version 12.0; SPSS Inc., Chicago, IL) was uti-
lized in the analyses.
Results
Patient characteristics
A total of 114 patients were included in the current analy-
ses (Table 1). They comprised 67 males and 47 females,
with a median age of 59 years (range, 28–84 years). Sixty
seven patients (58.8%) evidenced tumor sizes of ≥ 4 cm.
Tumor penetrated serosa or involved adjacent structures
were observed in 37 patients (32.5%). Seventy three
patients (64%) had LN metastasis. The postoperative
stages of patients were I, II, III, and IV in 42, 25, 31, and
16 patients, respectively. There was no distant metastasis.
Clinicopathological significance of HIF-1α, VEGF, and p53 
protein expression
The relationships between HIF-1α, VEGF, p53 protein
expression levels and clinicopathologic variables are pro-
vided in Figure 1 and Table 2. The positive rates of p53
and HIF-1α (diffuse, deep, intravascular pattern) were
38.6% and 15.8%, respectively. The VEGF overexpression
rate was 57.9%. p53 and HIF-1α (diffuse, deep, intravas-
cular pattern) were correlated positively with invasion
depth (P = 0.015, P = 0.001, respectively). p53 was corre-
lated significantly with LN involvement (P = 0.04). Corre-
lations between VEGF overexpression and pathological
status were not statically significant. However, VEGF over-
expression was observed more frequently in the old age
group (≥ 60 years old) and intestinal type (P = 0.013, P =
0.014, respectively).
Clinicopathological significance of preoperative sVEGF 
levels
We noted a significant correlation between sVEGF levels
and tumor size with higher sVEGF levels detected at the ≥
4 cm tumor size (P = 0.002). Although the relationship
between sVEGF levels and the invasion depth of the
tumor was not statistically significant (P  = 0.565), the
presence of LN involvement was statistically significant (P
= 0.010). Cut-off value of preoperative sVEGF for survival
analysis was 105 pg/ml by ROC curve. 53.5% of patients
had elevated preoperative sVEGF than cut-off value.
Prognostic significance of preoperative sVEGF level, HIF-
1α, VEGF, and p53 protein expression
The median follow-up duration was 24.5 months (range,
14–32 months) after operation. HIF-1α (diffuse, deep,
intravascular pattern) was observed to be a poor prognos-
tic factor for disease recurrence or progression (P = 0.002)
(Figure 2). However, we noted no significant association
between the other factors and disease progression or
patient overall survival.
Table 1: Clinicopathological features
No. of patients %


























I4 2 3 6 . 8
II 25 21.9
III 31 27.2
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Association between HIF-1α, p53, and VEGF expression 
and preoperative sVEGF level
Although HIF-1α, p53, and VEGF expression and preoper-
ative sVEGF level were correlated with several clinico-
pathologic findings, correlations between each factor were
not observed (Table 3).
Discussion
Tumor angiogenesis and neovascularization require VEGF
expression and the binding of HIF-1α to the VEGF pro-
moter is a major pathway resulting in the induction of
VEGF expression under hypoxic conditions [10]. HIF-1α
overexpression has been detected via IHC in several
human cancers, including those of the brain, bladder,
breast, colon, ovary, pancreas, kidney, and prostate [11-
17]. Furthermore, HIF-1α overexpression is significantly
correlated with highly aggressive disease and poor prog-
nosis in some cancer types, including breast, ovarian, oli-
godendroglioma, and oropharyngeal cancers
[13,14,18,19]. Our data also indicate that increasing HIF-
1α expression performs an important function in tumor
invasiveness and correlation with the TNM stage. In our
study, HIF-1α expression grouping was different from that
reported in previous studies. Because gastric cancer mass
is not generally associated with tissue necrosis, like aggres-
sive solid tumors (ex. glioblastoma multiforme) and HIF-
1α is also expressed in benign ulcer lesions, particularly in
the healing state [20], we classified the group of HIF-1α
expression as a negative/superficial and deep/diffuse/vas-
cular invasion pattern. Actually, in this study, superficial
HIF-1α expressing patients' (limited within mucosa and
submucosa) clinicopathological patterns were similar to
those evidenced by HIF-1α negative patients.
In addition to the role of HIF-1α as a DNA-binding pro-
tein, HIF-1α has also been shown to exert biological
effects via protein-protein interactions. Under hypoxic
conditions, HIF-1α has been shown to interact with the
tumor suppressor protein p53, which itself is a DNA-bind-
ing force for p53 loss of function in gastric cancer [7]. The
prognostic value of p53 remains controversial, as the
majority of previous studies have reported an association
of p53 with patient survival [21], while some other inves-
tigations contradict these findings [22]. In our study, p53
expression was correlated with tumor size, tumor inva-
sion, and LN metastasis. However, we noted no associa-
tion between the expressions of HIF-1α and VEGF.
Survival prognostic predictivity was also not observed.
Tumor VEGF expression was shown to be a significant
marker for tumor recurrence or reduced survival inde-
pendent of conventional clinicopathological variables in
several cancers [23]. In cases of gastric cancer, a positive
correlation between VEGF expression and lymphatic inva-
sion, LN metastasis, venous invasion, and patient out-
come has been reported by several groups [21,24,25], but
there are also published reports that contradict this notion
[26,27]. In our observations, VEGF overexpression is not
correlated with clinopathological findings except in the
elderly and in cases of intestinal-type gastric cancer.
Immunohistochemical staining of HIF-1α, p53, and VEGF Figure 1
Immunohistochemical staining of HIF-1α, p53, and VEGF. Sites of positive expression of HIF-1α; superficial (a), deep-
sited (b), diffuse (c), and vascular invasion (d). Cytoplasmic immunostaining of p53 (e). Underexpression (f) and overexpression 
(g) of VEGF. Original magnifications: ×200.BMC Cancer 2008, 8:123 http://www.biomedcentral.com/1471-2407/8/123
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Although we evaluated cytoplasmic VEGF expression
including proportion and intensity, the results remained
the same.
Higher preoperative sVEGF levels have been reported in
gastric cancer patients as compared with healthy controls,
and this has been clinically correlated with stage, and the
presence of distant metastasis [28-31]. In our study,
Table 2: Correlation between the expression of HIF-1α, p53, VEGF, and preoperative sVEGF level and clinicopathological parameters
p53 HIF-1α VEGF sVEGF
- + P* -/S D/V P* U O P* Median (range) P†
Total 70 44 96 18 48 66 (pg/ml)
Gender
Male 67 (58.8) 37 30 0.106 57 10 0.763 24 43 0.105 82 (6–1076) 0.275
Female 47 (41.2) 33 14 39 8 24 23 158 (7–642)
Age
<60 58 (50.9) 36 22 0.882 49 9 0.935 31 27 0.013 112 (6–622) 0.309
≥ 60 56 (49.1) 34 22 47 9 17 39 121 (6–1076)
Tumor size
<4 cm 47 (41.2) 34 13 0.045 43 4 0.061 19 18 0.761 76 (6–495) 0.002
≥4 cm 67 (58.8) 36 31 53 14 29 38 167 (6–1076)
T stage
T0,1 29 (25.5) 24 5 0.015 28 1 0.001 12 17 0.748 T0–2 0.565
T2 48 (42.1) 28 20 42 6 23 25 103 (6–1076)
T3 31 (27.2) 14 17 23 8 10 21 T3–4
T4 6 (5.3) 4 2 3 3 3 3 165 (8–504)
LN meta
Negative 41 (35.9) 30 11 0.040 38 3 0.051 17 24 0.917 77 (6–477) 0.010
Positive 73 (64.1) 40 33 58 15 31 42 156 (6–1076)
TNM stage
I 42 (36.8) 30 12 0.296 39 3 0.022 17 25 0.840 Stage I-II 0.382
II 25 (21.9) 15 10 21 4 14 11 96 (6–1076)
III 31 (27.2) 13 18 25 6 7 24 Stage III-IV
IV 16 (14.0) 12 4 11 5 10 6 158 (8–504)
Lauren
Intestinal 45 (51.7) 26 19 0.393 39 9 0.387 14 31 0.014 96 (6–1076) 0.294
Diffuse 42 (48.3) 28 14 37 5 24 18 154 (8–633)
P * by χ2 test, P† by Mann-Whitney U test
HIF-1α: hypoxia-inducible factor 1 alpha, VEGF: vascular endothelial growth factor, sVEGF: preoperative serum vascular endothelial growth factor, 
LN: lymph node, -/s: negative/superficial pattern, d/v: deep/diffuse/vascular invasion pattern, U: under-expressed, O: over-expressed
Table 3: Correlation of HIF-1α, p53, and VEGF expression with preoperative sVEGF level
p53 HIF-1α VEGF
-+ P -/S D/V P Under Over P
HIF-1α
-/S 58 38 0.617*
D/V 12 6
VEGF
Under 33 15 0.169* 40 8 0.827*
Over 37 29 56 10
sVEGF (pg/ml)
Median 103 139 0.705† 147 77 0.438† 153 163 0.146†
(range) (8–1076) (6–642) (6–1076) (6–761) (8–1076) (6–761)
* by χ2 test, † by Mann-Whitney U test
HIF-1α: hypoxia-inducible factor 1 alpha, VEGF: vascular endothelial growth factor, sVEGF: preoperative serum vascular endothelial growth factor, 
-/S: negative/superficial pattern, D/V: deep/diffuse/vascular invasion pattern, Under: under-expressed, Over: over-expressedBMC Cancer 2008, 8:123 http://www.biomedcentral.com/1471-2407/8/123
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tumor size and LN metastasis were correlated with sVEGF
levels.
HIF-1α, p53, and VEGF expression have been reported to
be positively correlated. However, correlations between
preoperative sVEGF level and tissue HIF-1α, VEGF, and
p53 were not observed in this study. These results, which
differ from those of other studies, may be attributable to
differences in the methods of the studies, including the
criteria of positivity and the number of patients studied.
Additionally, sVEGF is regulated by several potential tran-
scription factor-binding sites, including HIF-1α, activator
protein 1, activator protein 2, Egr-1, Sp1, and a host of
others. Furthermore, angiogenesis is influenced by several
endogenous pro-angiogenic factors and anti-angiogenic
factors [10]. Further studies will be required in order to
determine the definitive mechanisms inherent to meta-
static pathogenesis, thus allowing us to develop more
effective cancer treatments.
Conclusion
Our data also indicate that p53, HIF-1α, and preoperative
sVEGF could be markers of invasion depth or LN involve-
ment. Although the median follow-up duration was too
short to analyze, HIF-1α expression was found to be a
poor prognostic factor for disease recurrence or progres-
sion in patients with gastric cancer.
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